ENXTAM:MT
ENXTAM:MTMetals and Mining

Is ArcelorMittal’s 1GW India Renewables Push Altering The Investment Case For ArcelorMittal (ENXTAM:MT)?

In December 2025, ArcelorMittal announced three new renewable energy projects in India totaling 1GW of solar and wind capacity, with US$0.9 billion of capital expenditure, which will supply power to its AMNS India joint venture and lift its global renewable capacity to 3.3GW. This push effectively doubles the company’s renewable footprint in India to 2GW and underscores how decarbonization investments are becoming integral to its steelmaking operations. Next, we’ll explore how this 1GW...
ENXTAM:MTRK
ENXTAM:MTRKSoftware

European Penny Stocks To Consider In January 2026

As we enter 2026, the European market is experiencing a notable upswing, with the pan-European STOXX Europe 600 Index reaching new highs and closing 2025 with its strongest yearly performance since 2021. Amidst this positive economic backdrop, investors are increasingly exploring diverse opportunities within the stock market. Penny stocks, though often seen as remnants of past trading eras, continue to offer intriguing possibilities for those seeking affordable investments with growth...
ENXTAM:HEIO
ENXTAM:HEIOBeverage

Heineken (ENXTAM:HEIO) Valuation Check After Recent Outperformance in European Consumer Staples Sector

Heineken Holding (ENXTAM:HEIO) has quietly outperformed the broader European consumer staples space over the past month, and that strength is starting to catch investors attention as they reassess its longer term track record. See our latest analysis for Heineken Holding. Zooming out, Heineken Holding’s roughly 6 percent year to date share price return and double digit 1 year total shareholder return suggest momentum is gradually rebuilding as investors warm to its earnings recovery story. If...
ENXTAM:GLPG
ENXTAM:GLPGBiotechs

Did Strong GLPG5101 CAR T Data and Decentralized Manufacturing Just Shift Galapagos' (ENXTAM:GLPG) Investment Narrative?

Earlier in December 2025, Galapagos NV reported updated Phase 2 results from its ATALANTA-1 trial of CD19 CAR T-cell therapy GLPG5101 in heavily pretreated mantle cell lymphoma, showing very high response rates, durable outcomes at nine months, and an encouraging safety profile presented at the ASH Annual Meeting. Beyond efficacy, the trial also highlighted the feasibility of decentralized manufacturing, with most patients receiving a fresh GLPG5101 product within seven days of apheresis,...